3 active trials 2 recruiting 2 disease areas
| Phase 2 | 2 | |
| Phase 4 | 1 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT04790045 | Lymph Node Microenvironment Modifications in Patients With CLL Treated With… | Chronic Lymphocytic Leukemia | Not Yet Recruiting | 2023-10-03 |
| Phase 2 | ||||
| NCT04758975 | Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual… | Chronic Lymphocytic Leukemia (CLL) | Recruiting | 2023-10-04 |
| NCT04908228 | Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve… | Chronic Lymphocytic Leukemia | Recruiting | 2023-10-03 |
Leukemia (3) · Chronic Lymphocytic Leukemia (CLL) (3)